Alternatives to digitalis glycosides for heart failure.

C. Wathen,A. Muir

DOI: https://doi.org/10.1136/bmj.290.6478.1352-b

1985-05-04

British Medical Journal

Abstract:delayed puberty. I disagree, however, with the treatment he suggests for boys. For several years I have used human chorionic gonadotrophin 1000-2000 units intramuscularly twice weekly, for three to six months only, and have not encountered any "emotional" problems in these patients as a result of this treatment. Indeed, the only emotional problems for these patients stem from their physical and sexual immaturity. These doses quickly cause early changes of puberty, with improvement of the patient's emotional state and without excessive skeletal maturation compared to height increase. Thereafter puberty generally continues smoothly over the next two to three years, unless, of course, the patient has hypogonadotrophic hypogonadism. Follow up to their mid to late 20s of these successfully treated patients with constitutional delayed growth and development shows normal sexual orientation, social intercourse, and fertility. The very low doses of human chorionic gonadotrophin suggested by Dr Brook are unlikely to result in early pubertal changes and I believe that the teenagers I see would not tolerate this treatment for very long in the absence of clearly visible improvement of their physical and sexual development. In addition, pulsatile use of gonadotrophin releasing hormone as a treatment for teenage boys with delayed puberty is cumbersome, expensive, and unproved. Since there is a danger of down regulation of the gonadotroph, numerous blood samples are required to ensure that this treatment is not counterproductive. I believe that this, again, would not be tolerated by many teenagers. At present teenage boys, not concerned with fertility but only with overt physical and sexual development, should still be treated with human chorionic gonadotrophin, as described. Later, if puberty has not occurredfor example, in the occasional patient with congenital isolated hypogonadotrophic hypogonadism-androgen treatment should be given until fertility is desired. At this stage pulsatile gonadotrophin releasing hormone may be tried as an alternative to conventional human chorionic gonadotrophin and follicle stimulating hormone therapy. Properly conducted trials are required to assess these two forms of treatment for infertility in men due to hypogonadotrophic hypogonadism. Finally, your leading article failed to emphasise that growth hormone deficiency should always be excluded, with growth measurements and pituitary function tests, before starting treatment to induce puberty, to ensure that bone fusion does not occur in the absence of height increase. H N COHEN Stonehouse Hospital, Stonehouse, Lanarkshire ML9 3N1